Hochschulschrift
Overexpression of Heat-Shock Protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through s-phase arrest and apoptosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
München, Ludwig-Maximilians-Universität, Diss., 2014
- Schlagwort
-
Krebs
Onkologie
- Ereignis
-
Veröffentlichung
- (wo)
-
München
- (wer)
-
Universitätsbibliothek der Ludwig-Maximilians-Universität
- (wann)
-
2014
- Urheber
-
Guo, Yang
- Beteiligte Personen und Organisationen
-
Schnurr, Max
- URN
-
urn:nbn:de:bvb:19-176979
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
- Guo, Yang
- Schnurr, Max
- Universitätsbibliothek der Ludwig-Maximilians-Universität
Entstanden
- 2014
Ähnliche Objekte (12)
XAF1 overexpression exacerbates diabetes by promoting pancreatic β-cell apoptosis
Beclin1 inhibition promotes autophagy and decreases gemcitabine–induced apoptosis in Miapaca2 pancreatic cancer cells
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Requirement of nuclear factor κb for smac mimetic–mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis
Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Erratum to: Clusterin confers gemcitabine resistance in pancreatic cancer
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
XAF1 overexpression exacerbates diabetes by promoting pancreatic β-cell apoptosis
Beclin1 inhibition promotes autophagy and decreases gemcitabine–induced apoptosis in Miapaca2 pancreatic cancer cells
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Requirement of nuclear factor κb for smac mimetic–mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis
Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Erratum to: Clusterin confers gemcitabine resistance in pancreatic cancer
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
XAF1 overexpression exacerbates diabetes by promoting pancreatic β-cell apoptosis
Beclin1 inhibition promotes autophagy and decreases gemcitabine–induced apoptosis in Miapaca2 pancreatic cancer cells
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Requirement of nuclear factor κb for smac mimetic–mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis
Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Erratum to: Clusterin confers gemcitabine resistance in pancreatic cancer
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer